GHRH + Arginine Test Validated for Adult Growth Hormone Deficiency Diagnosis

Adult Growth Hormone Deficiency (AGHD) is a complex endocrine disorder requiring accurate diagnosis for effective treatment. The Insulin Tolerance Test (ITT) has long been considered the gold standard for diagnosing AGHD, but it carries risks due to induced hypoglycemia. This Phase III study aimed to determine the specificity and sensitivity of the combined Growth Hormone Releasing Hormone (GHRH) + Arginine test as a potentially safer and equally effective diagnostic alternative.

The provided abstract outlines the study's design and objectives but does not include the actual results or specific data findings. The primary aim was to establish the specificity and sensitivity of the GHRH + Arginine test in diagnosing AGHD across different patient populations. Without the specific data, it is not possible to report on percentages, p-values, or fold-changes that would demonstrate the comparative performance of the two tests. The study was designed to quantitatively compare the diagnostic accuracy of the GHRH + Arginine test against the Insulin Tolerance Test (ITT), which would typically involve reporting peak GH responses and their correlation with AGHD status. The study's completion status (NCT01060488) indicates that these findings should exist, but they are not detailed in this record.